Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 22, 2026
Abbott to buy Exact Sciences for $21B in cancer diagnostics reach push
11:03am, Thursday, 20'th Nov 2025
Abbott Laboratories (NYSE:ABT) on Thursday announced a definitive agreement to acquire cancer diagnostics company Exact Sciences (NASDAQ:EXAS) in a deal valued at approximately $21 billion. Exact Scie
Exact Sciences Soars As Abbott Unveils $21 Billion Buyout
10:21am, Thursday, 20'th Nov 2025
Exact Sciences (EXAS) kept rallying on Thursday, climbing another ~18% in premarket trading after Abbott (ABT) officially confirmed it will acquire the cancer-t
Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics
09:37am, Thursday, 20'th Nov 2025
Abbott Laboratories (NYSE: ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ: EXAS) for $105 per common share, representing a total equity value of approximately
EXAS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Exact Sciences Corporation is Fair to Shareholders
09:03am, Thursday, 20'th Nov 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Exact Sciences Corporation (NASDAQ: EXAS) to Abbott for $105.00 per common share in cash
Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test
08:43am, Thursday, 20'th Nov 2025
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.
07:46am, Thursday, 20'th Nov 2025
Abbott Laboratories agrees to buy the cancer screening company in a cash deal.
Abbott to Acquire Exact Sciences for $21 Billion
07:46am, Thursday, 20'th Nov 2025
Abbott agreed to acquire Exact Sciences for $105 a share, representing a total equity value of about $21 billion.
Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences
07:36am, Thursday, 20'th Nov 2025
Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business.
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
07:30am, Thursday, 20'th Nov 2025
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics
Why Exact Sciences Stock Blasted Nearly 24% Higher Today
07:21pm, Wednesday, 19'th Nov 2025
The cancer diagnostics specialist might, just might, be on the verge of selling itself. The apparent would-be buyer is a top name in the U.S. pharmaceutical industry.
Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories
04:27pm, Wednesday, 19'th Nov 2025
A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.
Exact Sciences Catapults, Breaking Out, On Rumored Abbott Laboratories
03:21pm, Wednesday, 19'th Nov 2025
Exact Sciences stock catapulted Wednesday amid rumors Abbott Laboratories is nearing a deal to buy the cancer-finding specialist.
Abbott is weighing takeover of Exact Sciences, Bloomberg News reports
01:50pm, Wednesday, 19'th Nov 2025
Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg News reported on Wednesday, citing people familiar with the matter.
Exact Sciences Corporation (EXAS) Presents at Jefferies London Healthcare Conference 2025 Transcript
09:28am, Tuesday, 18'th Nov 2025
Exact Sciences Corporation ( EXAS ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST Company Participants Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief Fina
Exact Sciences Corporation $EXAS Shares Purchased by Allworth Financial LP
03:42am, Monday, 17'th Nov 2025
Allworth Financial LP increased its holdings in Exact Sciences Corporation (NASDAQ: EXAS) by 130.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Comm
